RT Journal Article
SR Electronic
T1 Age-adjusted Charlson comorbidity index score is the best predictor for severe clinical outcome in the hospitalized patients with COVID-19 infection: a result from nationwide database of 5,621 Korean patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.26.20220244
DO 10.1101/2020.10.26.20220244
A1 Do Hyoung Kim
A1 Hayne Cho Park
A1 Ajin Cho
A1 Juhee Kim
A1 Kyu-sang Yun
A1 Jinseog Kim
A1 Young-Ki Lee
YR 2020
UL http://medrxiv.org/content/early/2020/10/27/2020.10.26.20220244.abstract
AB Aged population with comorbidities demonstrated high mortality rate and severe clinical outcome in the patients with coronavirus disease 2019 (COVID-19). However, whether age-adjusted Charlson comorbidity index score (CCIS) predict fatal outcomes remains uncertain. This retrospective, nationwide cohort study was performed to evaluate patient mortality and clinical outcome according to CCIS among the hospitalized patients with COVID-19 infection. We included 5,621 patients who had been discharged from isolation or had died from COVID-19 by April 30, 2020. The primary outcome was composites of death, admission to intensive care unit (ICU), use of mechanical ventilator or extracorporeal membrane oxygenation. The secondary outcome was mortality. Multivariate Cox proportional hazard model was used to evaluate CCIS as the independent risk factor for death. Among 5,621 patients, the high CCIS (≥3) group showed higher proportion of elderly population and lower plasma hemoglobin and lower lymphocyte and platelet counts. The high CCIS group was an independent risk factor for composite outcome (HR 3.63, 95% CI 2.45-5.37, P < 0.001) and patient mortality (HR 22.96, 95% CI 7.20-73.24, P < 0.001). The nomogram demonstrated that the CCIS was the most potent predictive factor for patient mortality. The predictive nomogram using CCIS for the hospitalized patients with COVID-19 may help clinicians to triage the high-risk population and to concentrate limited resources to manage them.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Institutional Review Board of the Kangnam Sacred Heart Hospital, Seoul, Korea (HKS 2020-06-025). The informed consent was waived by the Institutional Review Board due to retrospective nature of the study. All research was performed in accordance with relevant guidelines and regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from KCDC, but restrictions apply to the availability of these data and so are not publicly available. Data are however available from the authors upon request and with permission of KCDC.